Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder: A randomized controlled trial

Journal of Clinical Psychiatry

Volumn 74, Issue 2, 2013, Pages 158-166

  Rosenthal, Joshua Z ^a   Boyer, Patrice ^b,c   Vialet, Cécile ^d   Hwang, Eunhee ^d   Tourian, Karen A ^d  

^a Capital Clinical Research Associates   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DESVENLAFAXINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; CHRONIC DRUG ADMINISTRATION; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; ELECTROCARDIOGRAPHY; FEMALE; HAMILTON SCALE; HEADACHE; HOSPITALIZATION; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTPATIENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RELAPSE; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; UNPLANNED PREGNANCY; WEIGHT CHANGE; XEROSTOMIA;

EID: 84874606055     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m07974     Document Type: Article

References (47)

1. Vuorilehto M, Melartin T, Isometsä E. Depressive disorders in primary care: recurrent, chronic, and co-morbid. Psychol Med. 2005;35(5):673-682. doi:10.1017/S032917040370 PubMed (Pubitemid 40716431)
2. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370(9590):851-858. doi:10.1016/S0140-6736(07)61415-9 PubMed (Pubitemid 47362344)
3. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2-3):97-108. doi:10.1016/S0165-0327(98) 0138-4 PubMed (Pubitemid 28551779)
4. McGrath PJ, Stewart JW, Quitkin FM, et al. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry. 2006;163(9):1542-1548. doi:10.176/api.ajp.163.9.1542 PubMed (Pubitemid 44465753)
5. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR.*D report. Psychol Med. 2010;40(1):41-50. doi:10.1017/S032917090601 PubMed
6. Rucci P, Frank E, Calugi S, et al. Incidence and predictors of relapse during continuation treatment of major depression with SSRI, interpersonal psychotherapy, or their combination. Depress Anxiety. 2011;28(11):955-962. doi:10.102/da.20894 PubMed
7. Vuorilehto MS, Melartin TK, Isometsä ET. Course and outcome of depressive disorders in primary care: a prospective 18-month study. Psychol Med. 2009;39(10):1697-1707. doi:10.1017/S0329170905182 PubMed
8. Wang JL, Patten SB, Currie S, et al. Predictors of 1-year outcomes of major depressive disorder among individuals with a lifetime diagnosis: a population-based study [published online ahead of print July 11, 2011]. Psychol Med. 2011;1-10. PubMed
9. ten Doesschate MC, Bockting CL, Koeter MW, et al; DELTA Study Group. Prediction of recurrence in recurrent depression: a 5.5-year prospective study. J Clin Psychiatry. 2010;71(8):984-991. doi:10.408/JCP.08m04858blu PubMed
10. Hardeveld F, Spijker J, De Graaf R, et al. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2010;122(3):184-191. doi:10.1/j.160-047.209.01519.x PubMed
11. Glue P, Donovan MR, Kolluri S, et al. Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Aust N Z J Psychiatry. 2010;44(8):697-705. doi:10.3109/0486710370541 PubMed
12. Williams N, Simpson AN, Simpson K, et al. Relapse rates with long-term antidepressant drug therapy: a meta-analysis. Hum Psychopharmacol. 2009;24(5):401-408. doi:10.102/hup.103 PubMed
13. Hansen R, Gaynes B, Thieda P, et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv. 2008;59(10):1121-1130. doi:10.176/api.ps.59.10.121 PubMed
14. Work Group on Major Depressive Disorder. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Arlington, VA: American Psychiatric Association; 2010.
15. Nutt DJ, Davidson JR, Gelenberg AJ, et al. International consensus statement on major depressive disorder. J Clin Psychiatry. 2010;71(suppl e1):e08. PubMed
16. Davidson Jr. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71(suppl e1):e04. PubMed
17. Hylan TR, Crown WH, Meneades L, et al. SSRI antidepressant drug use patterns in the naturalistic setting: a multivariate analysis. Med Care. 1999;37(suppl Lilly):AS36-AS44. doi:10.1097/05650-190401-PubMed
18. Crown WH, Treglia M, Meneades L, et al. Long-term costs of treatment for depression: impact of drug selection and guideline adherence. Value Health. 2001;4(4):295-307. PubMed (Pubitemid 32756814)
19. Sawada N, Uchida H, Suzuki T, et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry. 2009;9(1):38. doi:10.186/1471-24X-9-38 PubMed
20. Serna MC, Cruz I, Real J, et al. Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry. 2010;25(4):206-213. doi:10.1016/j.eurpsy.209.07.012 PubMed
21. Esposito D, Wahl P, Daniel G, et al. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States. Clin Ther. 2009;31(3):644-656. doi:10.1016/j.clinthera. 209.03.012 PubMed
22. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer Inc; 2011.
23. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23(5):243-253. doi:10.1097/YIC.0b013e32830cebed PubMed
24. Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24(7):1877-1890. doi:10.185/030790802161923 PubMed
25. Dunlop BW, Reddy S, Yang L, et al. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011;31(5):569-576. doi:10.1097/JCP.0b013e3182c0a68 PubMed
26. Thase ME, Kornstein SG, Germain JM, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009;14(3):144-154. PubMed
27. Ferguson J, Tourian KA, Rosas GR, et al. A 12-month open-label evaluation of long-term safety and efficacy of desvenlafaxine succinate in outpatients with major depressive disorder. Poster presented at: Annual Meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, CA.
28. Tourian KA, Pitrosky B, Padmanabhan SK, et al. A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder. Prim Care Companion CNS Disord. 2011;13(2). PubMed
29. Rickels K, Montgomery SA, Tourian KA, et al. Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. J Clin Psychopharmacol. 2010;30(1):18-24. doi:10.1097/JCP. 0b013e3181c94c4d PubMed
30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
31. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: US Department of Health, Education, and Welfare; 1976:217-222.
32. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57. PubMed (Pubitemid 29001829)
33. Medical Dictionary for Regulatory Activities (MedDRA). http://www.meddramsso.com/. Accessed October 31, 2012.
34. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277. doi:10.176/api.ajp.201.101704 PubMed
35. Clayton AH, Kornstein SG, Rosas G, et al. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr. 2009;14(4):183-195. PubMed
36. Perahia DG, Gilaberte I, Wang F, et al. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry. 2006;188(4):346-353. doi:10.192/bjp.18.4.346 PubMed
37. Simon JS, Aguiar LM, Kunz NR, et al. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res. 2004;38(3):249-257. doi:10.1016/j.jpsychires.203.10.04 PubMed (Pubitemid 38299162)
38. Entsuah AR, Rudolph RL, Hackett D, et al. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol. 1996;11(2):137-145. PubMed (Pubitemid 26195890)
39. Schmidt ME, Fava M, Robinson JM, et al. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry. 2000;61(11):851-857. doi:10.408/JCP.v61n107 PubMed
40. Reimherr FW, Amsterdam JD, Quitkin FM, et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry. 1998;155(9):1247-1253. PubMed (Pubitemid 28402520)
41. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry. 2004;65(1):44-49. doi:10.408/JCP.v65n0107 PubMed
42. Greenhouse JB, Stangl D, Kupfer DJ, et al. Methodologic issues in maintenance therapy clinical trials. Arch Gen Psychiatry. 1991;48(4):313-318. doi:10.101/archpsyc.191.018102802904 PubMed
43. Montgomery SA, Fava M, Padmanabhan SK, et al. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol. 2009;24(6):296-305. doi:10.1097/YIC.0b013e32832fb5a PubMed
44. Montgomery SA, Rasmussen JG, Tanghøj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol. 1993;8(3):181-188. doi:10.1097/04850- 1930830-08 PubMed (Pubitemid 23294925)
45. Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol. 1995;10(suppl 1):29-35. doi:10.1097/04850-1950301-06 PubMed
46. Gorwood P, Weiller E, Lemming O, et al. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry. 2007;15(7):581-593. doi:10.1097/01.JGP.0240823.9452.4c PubMed
47. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol. 1993;8(3):189-195. doi:10.1097/04850-1930830-09 PubMed (Pubitemid 23294926)